Last reviewed · How we verify
fIPV (0.2mL) IM
fIPV is an inactivated polio vaccine that stimulates the immune system to produce antibodies against all three poliovirus serotypes, preventing polio infection.
fIPV is an inactivated polio vaccine that stimulates the immune system to produce antibodies against all three poliovirus serotypes, preventing polio infection. Used for Prevention of poliomyelitis caused by poliovirus serotypes 1, 2, and 3.
At a glance
| Generic name | fIPV (0.2mL) IM |
|---|---|
| Sponsor | Centers for Disease Control and Prevention |
| Drug class | Inactivated viral vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
fIPV contains chemically inactivated (killed) poliovirus particles of serotypes 1, 2, and 3. When administered intramuscularly, it triggers both humoral (antibody) and cellular immune responses without causing disease. The vaccine induces production of neutralizing antibodies that protect against infection if the vaccinated individual is exposed to wild-type or vaccine-derived poliovirus.
Approved indications
- Prevention of poliomyelitis caused by poliovirus serotypes 1, 2, and 3
Common side effects
- Injection site soreness, redness, or swelling
- Fever
- Irritability or fussiness
- Drowsiness
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- fIPV (0.2mL) IM CI brief — competitive landscape report
- fIPV (0.2mL) IM updates RSS · CI watch RSS
- Centers for Disease Control and Prevention portfolio CI